Breast Neoplasms (Breast Cancer)

58730 relevant articles (3461 outcomes, 12644 trials/studies) found for this Disease

Description: Tumors or cancer of the human BREAST.

Also Known As:

Breast Cancer; Cancer, Breast; Breast Tumors; Neoplasms, Breast; Cancer of Breast; Cancer of the Breast; Human Mammary Carcinoma; Mammary Carcinoma, Human; Mammary Neoplasm, Human; Mammary Neoplasms, Human; Tumors, Breast; Breast Neoplasm; Breast Tumor; Carcinoma, Human Mammary; Carcinomas, Human Mammary; Human Mammary Carcinomas; Human Mammary Neoplasm; Human Mammary Neoplasms; Mammary Carcinomas, Human; Neoplasm, Breast; Neoplasm, Human Mammary; Neoplasms, Human Mammary; Tumor, Breast

Subscribe to New Research on Breast Neoplasms

Relationship Network

Disease Context: Research Results

Neoplasms: 377660

Neoplasms by Site: 1

Breast Neoplasms: 58730

Male Breast Neoplasms: 199

Phyllodes Tumor: 147

Breast Ductal Carcinoma: 69

Skin and Connective Tissue Diseases

Skin Diseases: 5841

Breast Diseases: 915

Breast Neoplasms: 58730

Male Breast Neoplasms: 199

Phyllodes Tumor: 147

Breast Ductal Carcinoma: 69

Related Diseases

1.	Neoplasms (Cancer)
2.	Neoplasm Metastasis (Metastasis)
3.	Carcinoma (Carcinomatosis)
4.	Breast Neoplasms (Breast Cancer)
5.	Osteoporosis
897 Diseases and 17556 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Breast Neoplasms:

1.	Tamoxifen FDA LinkGeneric 04/01/2001 - "If women with a family history of breast cancer are being counseled regarding decisions on genetic testing, tamoxifen use, or other preventive measures, presenting both Claus and Gail estimates may be the best option." 08/01/2000 - "Tamoxifen is one of the most effective treatments for breast cancer" 11/03/1999 - "CONCLUSIONS: Tamoxifen is most beneficial for younger women with an elevated risk of breast cancer" 11/01/2002 - "The anti-oestrogen tamoxifen is very effective in the treatment and prevention of breast cancer" 08/01/2001 - "Tamoxifen has proven to be effective in improving relapse-free and overall survival in both pre- and postmenopausal women with ER(+) early-stage breast cancer" Get all the results and reference details, order at left...
2.	Estrogens (Estrogen)FDA Link 03/01/2000 - "The current study was conducted to investigate the efficacy of GAP31 and MAP30 on estrogen-independent and highly metastatic human breast tumor MDA-MB-231 both in vitro and in vivo" 05/01/1992 - "The results of this study with human breast cancer cells suggest that 5a may be highly effective in the treatment of estrogen-dependent breast cancer and/or in the prophylactic treatment of women with a high risk of breast cancer development." 12/01/2007 - "MDA-MB-231 is an estrogen receptor negative highly invasive human breast cancer cell line and has been used as a relevant model system to evaluate drugs with chemopreventive potential against highly invasive breast cancer phenotypes" 06/01/1983 - "Breast tumors are known to be heterogeneous with respect to estrogen receptor (ER) status, and the low complete remission rate may be secondary to this biochemical heterogeneity" 01/01/1983 - "Estrogen receptor (ER) has been well documented as an important predictor of long disease-free intervals and survival for patients with primary breast cancer (1)" Get all the results and reference details, order at left...
3.	Paclitaxel (Taxol)FDA LinkGeneric 09/01/2005 - "Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks." 01/01/1993 - "Taxol is an important new antitumor agent with demonstrated efficacy in ovarian and breast cancer" 01/01/2007 - "It is therefore concluded that paclitaxel in combination with seal oil demonstrated enhanced cytotoxicity and apoptosis in MCF-7 and MDA-MB-231 cells compared to paclitaxel alone, and the use of seal oil may be beneficial in the treatment of breast cancer." 02/01/2004 - "It may be concluded that the addition of paclitaxel to anthracycline-based therapy resulted in a statistically significant improvement in outcome in patients with ER-negative inflammatory breast cancer." 02/15/2001 - "Significant influences on adoption included use of symposia as a therapy information source, physician experience with paclitaxel to treat late-stage breast cancer, and perceived advantage in efficacy of paclitaxel" Get all the results and reference details, order at left...
4.	HormonesIBA 01/01/2007 - "Our data indicate that hCG, like pregnancy, induces permanent genomic changes that are not reproduced by steroid hormones and in addition regulates gene expression through epigenetic mechanisms that are differentiation-dependent processes, leading us to conclude that hormonally induced differentiation offers enormous promise for the primary prevention of breast cancer." 02/07/2004 - "We report the findings of the safety analysis in HABITS (hormonal replacement therapy after breast cancer--is it safe?), an open randomised clinical trial with allocation to either HRT or best treatment without hormones" 01/01/2003 - "The assessment of steroid hormone receptors in resected breast cancer tissues is essential to decide whether endocrine therapy is indicated and to select the best treatment for each patient on the basis of receptor status" 08/01/2002 - "Currently it is the most widely used agent for first line treatment against hormone sensitive metastatic breast cancer and the only approved hormonal agent for adjuvant treatment of organ confined breast cancer" 05/01/2004 - "Hormone receptor status has long been considered important in predicting the efficacy of endocrine agents for the treatment of breast cancer" Get all the results and reference details, order at left...
5.	trastuzumab (Herceptin)FDA Link 06/01/2002 - "Hopefully, information from these trials will help resolve questions regarding the efficacy of various combinations and dosing schedules so that trastuzumab may be used most effectively in the treatment of HER2-overexpressing breast cancer in both the metastatic and the adjuvant settings." 03/01/2002 - "In most patients with metastatic breast cancer, the risk of CD can be justified given the improvement in overall survival previously reported with trastuzumab." 09/01/2007 - "In the absence of randomized trials, the optimal duration of trastuzumab administration after achieving complete remission of metastatic breast cancer remains questionable." 07/01/2004 - "CONCLUSION: These studies suggest that (225)Ac-labeled trastuzumab may be a potent therapeutic agent against metastatic breast cancer cells exhibiting intermediate to high HER2/neu expression." 12/01/2003 - "With trastuzumab achieving excellent results in the treatment of HER-2/neu-positive advanced disease and under extensive evaluation in major clinical trials for its potential efficacy when used at earlier clinical stages, the potential role(s) for HER-2/neu testing as a predictor of response to other therapies being resolved by large prospective clinical outcome studies, and the more convenient gene-based chromogenic in situ hybridization technique "waiting in the wings," the saga of HER-2/neu testing in breast cancer will continue to unfold over the next several years." Get all the results and reference details, order at left...
6.	Doxorubicin (Adriamycin)FDA LinkGeneric 01/01/1996 - "The data developed here, including recent clinical trials of high-dose infusional doxorubicin, demonstrate the safety and efficacy of doxorubicin administration at doses > or = 150 mg/m2 for patients with breast cancer and strongly suggest that the utility of this drug can be substantially increased with appropriate hematopoietic support." 10/01/1987 - "It is concluded that when given at 3-weekly intervals adriamycin is a more effective treatment for advanced breast cancer at higher rather than lower dosage." 03/01/1987 - "The results show that the combined regimens including HD-DDP in the treatment of breast cancer and NSCLC (remission rate 87% and 40%, respectively) are better than that including low-dose DDP (17% and 7%) (P less than 0.001, P less than 0.01) and that including adriamycin (30% and 13%) (P less than 0.001, P less than 0.05)" 11/16/2006 - "These studies show that the in vivo therapeutic index of doxorubicin can be improved by conjugation with a specific Vectocell peptide (DPV1047) through an ester linker to C14 of doxorubicin, in both colon and breast tumor models" 04/01/2007 - "Kinetics and mechanism of nanoparticle-mediated cellular drug delivery and therapeutic efficacy of nanoparticle-encapsulated doxorubicin were evaluated in two model breast cancer cell lines" Get all the results and reference details, order at left...
7.	docetaxel (Taxotere)FDA Link 10/01/2000 - "We consider intra-arterial infusion using docetaxel to be highly effective with few side effects in cases of advanced breast cancer." 06/01/1999 - "Docetaxel (Taxotere, Rhône-Poulenc Rorer, Antony, France) is highly effective in the first-line treatment of metastatic breast cancer, achieving an objective response rate of 61% (95% confidence interval, 52% to 69%)" 05/06/2003 - "Docetaxel (Taxotere), alone or in combination with other anticancer agents, has proven efficacy in the first- and second-line treatment of metastatic breast cancer" 07/01/2002 - "BACKGROUND: Docetaxel has proven efficacy in metastatic breast cancer" 09/01/2001 - "Although docetaxel (Taxotere; TXT), a taxoid anticancer drug, is clinically and experimentally very effective against breast cancer, its antitumor effect is of very short duration" Get all the results and reference details, order at left...
8.	Cyclophosphamide (Cytoxan)FDA Link 11/01/2000 - "Three cases of metastatic breast cancer, resistant to pre-chemo and/or endocrine therapy, markedly improved with UFT and cyclophosphamide oral combination therapy]" 12/15/1989 - "The authors conclude that a single cycle of high-dose cyclophosphamide intensification in metastatic breast cancer does not result in significantly improved responses or prolonged survival." 02/01/1996 - "To explore further this relationship, the present pilot study investigated the therapeutic efficacy of cyclophosphamide at intermediate dose in two groups of untreated patients with advanced breast cancer" 12/01/2007 - "CONCLUSION: Noninvasive assessment of (18)F-F-CP uptake using PET may potentially be helpful for predicting the response of breast tumors to cyclophosphamide before therapy begins." 06/01/2003 - "The marketing terms specify that it must be used in combination with cyclophosphamide, in the first-line treatment of metastatic breast cancer" Get all the results and reference details, order at left...
9.	Fluorouracil (Carac)FDA LinkGeneric 08/01/2000 - "BACKGROUND: The protracted continuous infusion (PCI) of 5-fluorouracil (5-FU) has proven in several studies an active and well tolerated treatment for advanced, pretreated breast cancer" 01/01/1995 - "Randomized trial comparing conventional intravenous bolus FEC and FEC with high-dose infusional 5-fluorouracil as first-line treatment of advanced breast cancer." 11/01/1998 - "CONCLUSION: High-dose EPI combined with CTX, 5-Fu is a safe and effective regimen for patients with advanced breast cancer worthy of further clinical trial." 12/01/2001 - "PATIENTS AND METHODS: In this retrospective study, the therapeutic efficacy and tolerability of CDDP and continuous infusion of 5-FU were evaluated in patients with pretreated metastatic breast cancer" 02/01/1998 - "These results provide further rationale for individualizing the 5-FU dose, thus reducing the risk of toxicity and/or improving therapeutic efficacy in patients with breast cancer." Get all the results and reference details, order at left...
10.	Epirubicin (Ellence)FDA LinkGeneric 09/01/1998 - "Intravenous administration of Epirubicin-RTU was considered to be useful for the treatment of breast cancer." 07/01/1990 - "A randomised controlled study is proposed to assess the impact of this potential modulation on the efficacy of epirubicin in advanced breast cancer." 01/01/2000 - "We retrospectively determined the administered dose intensity and the relative toxicity and efficacy of an epirubicin-containing regimen in patients with primary or metastatic breast cancer" 10/20/2005 - "PURPOSE: The aim of the study was to evaluate the predictive value of HER2 and topoisomerase IIalpha gene (TOP2A) for the efficacy of epirubicin in the adjuvant setting of breast cancer patients" 08/01/1991 - "We evaluated the efficacy of epirubicin in a phase II trial in breast cancer, as well as its cardiac toxicity" Get all the results and reference details, order at left...
5766 Drugs and Important Bio-Agents and 49350 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 10/01/1995 - "To make legitimate the wide adoption of the strategy involving primary chemotherapy, most breast cancer specialists correctly advocate that the initial promising results be validated through classic randomized trials" 04/01/2005 - "The TXL weekly regimen seems to be very effective in regressing breast tumors and can be given safely in the outpatient setting with an extremely high utility profile as neoadjuvant chemotherapy as well." 02/01/1996 - "Infusional ECarboF is a highly active, well-tolerated, outpatient regimen effective against advanced/metastatic breast cancer and now warrants evaluation against conventional chemotherapy in high-risk early breast cancer." 10/01/1995 - "Adjuvant therapy with either chemotherapy or hormonal therapy offers statistically significant benefits for most subsets of women with breast cancer that in many cases outweigh the risks of treatment, but the potential benefit will vary from patient to patient and by modality of therapy" 06/01/1994 - "CONCLUSION: High-dose chemotherapy and autologous PBSCT is a potentially highly effective treatment of women with metastatic and poor prognosis primary breast cancer" Get all the results and reference details, order at left...
2.	Adjuvant Chemotherapy 01/01/1990 - "Adjuvant chemotherapy is a well accepted concept in the treatment of breast cancer and has resulted in most clinical studies in a significant prolongation of the disease-free interval in certain subgroups of patients" 12/01/2005 - "Adjuvant chemotherapy is most cost-effective in pre-menopausal women with node-positive breast cancer while cost-effectiveness decreases considerably with increasing age" 01/01/2001 - "The proven benefits of adjuvant chemotherapy on disease-free and overall survival in breast cancer can be explained by concepts of cell kill" 01/01/2001 - "PATIENTS AND METHODS: From a randomized study in high-risk breast cancer patients on the efficacy of high-dose versus standard-dose adjuvant chemotherapy, late effects on cognitive functioning were analyzed by neuropsychological tests" 01/01/1986 - "Updated randomized trials using adjuvant chemotherapy for breast cancer have generally shown significantly improved disease-free survival in young women" Get all the results and reference details, order at left...
3.	Mastectomy (Mammectomy) 05/01/2003 - "Mastectomy and breast-conserving treatment have proven equally effective in terms of survival in early breast cancer, but studies continue to provide evidence that patients undergoing breast-conserving procedures have a better quality of life (QOL)" 01/01/1994 - "Prophylactic mastectomy may be beneficial in some women, but identification of individuals at very high risk for breast cancer remains elusive" 09/01/2005 - "While data are accumulating on the efficacy of prophylactic mastectomy as a means to reduce breast cancer risk in high risk women, the effectiveness of the procedure depends on women's interest in undergoing the procedure" 05/01/2005 - "The average disease-free interval from the initial mastectomy was significantly shorter in metastatic breast cancer patients (66.8 months), but disease-free intervals were longer than 5 years in 41.0% of metastatic breast cancer patients" 09/01/2004 - "Recent research has demonstrated that prophylactic mastectomy may be effective in preventing breast cancer in high-risk women, as well as those with a known BRCA1/2 mutation" Get all the results and reference details, order at left...
4.	Heterologous Transplantation (Xenotransplantation) 06/01/2008 - "We previously showed that AIIB2 had no discernible toxicity in mice; here, its addition allowed for a significant reduction in the IR dose that was necessary to achieve comparable growth inhibition and apoptosis in breast cancer xenografts in vivo." 02/01/2008 - "Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies." 03/01/1995 - "These results show that photochemically generated novel compounds in pMC540 are effective in suppressing the growth of established human MCF-7 and MDA-MB-435 breast tumor xenografts." 03/01/2006 - "The use of KGF-transfected breast cancer cells in the xenograft model may help to study the mechanism of KGF-mediated cell motility and to identify specific KGF antagonists that may be used to prevent or impede KGF-mediated metastatic progression." 12/01/2006 - "Improved anti-tumoral capacity of mixed and pure anti-oestrogens in breast cancer cell xenografts after their administration by entrapment in colloidal nanosystems." Get all the results and reference details, order at left...
5.	Combination Drug Therapy (Combination Chemotherapy) 08/01/1996 - "Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer." 12/01/1984 - "In the past decade, combination chemotherapy has resulted in significant improvement of survival in patients with disseminated breast cancer, and with this approach a small fraction of patients with metastatic disease have remained in extended complete remission" 12/01/1979 - "One hundred sixteen patients with metastatic breast cancer who achieved complete remission with combination chemotherapy were analyzed to ascertain the factors that affect the duration of complete remission and the patterns of relapse" 11/01/2002 - "BACKGROUND: To determine whether patients with high-risk metastatic breast cancer draw benefit from combination chemotherapy as first-line treatment" 05/01/1992 - "We confirmed that combination chemotherapy with a low dose of 5'-DFUR and MPA was effective for first line treatment of metastatic breast cancer." Get all the results and reference details, order at left...
291 Therapies and Procedures and 17227 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Patient-Physician Research Summary Report on Breast Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 3461 Outcomes
Top 200 Key Medications
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF for "Psoriasis" >>

Price:

$24.00 & Delivery via PDF download,
updates for 1 year

Proceed to Checkout >>

Research Interface Subscription

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Searches
2 clicks from Disease to Drug to Evidence
Trial references
All the Positive Outcomes
Drug and Therapy searches
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface Subscription

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>